Q4 25 EPS
$7.54
BEAT +5.16%
Est. $7.17
Q4 25 Revenue
$19.29B
BEAT +7.33%
Est. $17.97B
vs S&P Since Q4 25
-18.9%
TRAILING MARKET
LLY -12.5% vs S&P +6.4%
Full Year 2025 Results
FY 25 EPS
$24.21
BEAT +2.48%
Est. $23.62
FY 25 Revenue
$65.18B
BEAT +2.06%
Est. $63.86B
Market Reaction
Did LLY Beat Earnings? Q4 2025 Results
Eli Lilly closed out fiscal 2025 with a blowout fourth quarter, posting revenue of $19.29 billion, up 42.6% year-over-year and well ahead of the $17.97 billion consensus, while non-GAAP EPS of $7.54 beat the $7.17 estimate by 5.16%, reflecting the re… Read more Eli Lilly closed out fiscal 2025 with a blowout fourth quarter, posting revenue of $19.29 billion, up 42.6% year-over-year and well ahead of the $17.97 billion consensus, while non-GAAP EPS of $7.54 beat the $7.17 estimate by 5.16%, reflecting the relentless commercial momentum of its incretin franchise. The story behind the numbers is straightforward: Mounjaro revenue more than doubled to $7.41 billion and Zepbound surged 123% to $4.26 billion, together cementing Lilly's position as the GLP-1 category leader by a widening margin. Analysts and commentators have taken note, with price target upgrades following the print as confidence grows in the durability of the obesity and diabetes franchises. Looking ahead, Lilly guided 2026 revenue to a range of $80 billion to $83 billion, with non-GAAP EPS of $33.50 to $35.00, a forecast underpinned by the regulatory submission of oral GLP-1 candidate orforglipron across the U.S., Japan, and the EU, a potential catalyst that could meaningfully expand the company's addressable market beyond injectable therapies.
Key Takeaways
- • 46% volume growth driving worldwide revenue increase
- • Strong demand for Mounjaro and Zepbound
- • Mounjaro international revenue growth driven by volume expansion
- • Favorable product mix and improved cost of production supporting gross margins
- • Lower realized prices partially offsetting volume gains
LLY YoY Financials
Q4 2025 vs Q4 2024, source: SEC Filings
LLY Revenue by Segment
With YoY comparisons, source: SEC Filings
LLY Revenue by Geography
With YoY comparisons, source: SEC Filings
“2025 was an important year for Lilly. We reached millions more patients—launching Inluriyo, expanding Mounjaro and Kisunla globally, and submitting orforglipron for approval. We expanded our manufacturing capacity, and through our U.S. government agreement, opened new access to obesity medicines. Entering our 150th year with a deep pipeline and platforms like LillyDirect, we're positioned to reach more patients than ever and expand our global health impact.”
— David A. Ricks, Q4 2025 Earnings Press Release
LLY Earnings Trends
LLY vs Market 30 Day Price Reactions
30-day stock return vs benchmark after each earnings
LLY EPS Trend
Earnings per share: estimate vs actual
LLY Revenue Trend
Quarterly revenue: estimate vs actual
LLY Quarterly Results
5 quarters of earnings data
| Quarter | EPS Est. | EPS Act. | Surprise | Revenue | Rev. Surprise |
|---|---|---|---|---|---|
| Q1 26 | — | $8.55 | — | $19.80B | +11.25% |
| Q4 25 BEAT FY | $7.17 | $7.54 | +5.16% | $19.29B | +7.33% |
| FY Full Year | $23.62 | $24.21 | +2.48% | $65.18B | +2.06% |
| Q3 25 BEAT | $5.89 | $7.02 | +19.15% | $17.60B | +9.53% |
| Q2 25 BEAT | $5.59 | $6.31 | +12.89% | $15.56B | +6.06% |
| Q1 25 MISS | $3.46 | $3.34 | -3.39% | $12.73B | +0.05% |